# US 2026/0085158 A1 · Bacterial Beta-lactamase Responsive Hydrogels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085158 A1
- Document ID: US20260085158A1
- Status: Published application
- Kind: A1
- Application number: 19/408,590
- Filed: 2025-12-04
- Published: 2026-03-26
- Earliest claimed: 2019-10-28
- Assignees: Brown University
- Applicants: Brown University
- Inventors: Anita Shukla; Dahlia Alkekhia; Akram Abbasi
- Web page: https://patentgrep.com/patent/US20260085158A1

## CPC

- C08J 3/075: Macromolecular gels
- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- A61L 27/52: Hydrogels or hydrocolloids
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C08J 2300/208: Interpenetrating networks [IPN]
- C08J 2333/26: Homopolymers or copolymers of acrylamide or methacrylamide
- C08J 2405/16: Cyclodextrin; Derivatives thereof
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides a “host-guest” supramolecular hydrogel. The hydrogel contains an AAm/NVP interpenetrating polymer network (IPN) with supramolecular cross-linkers assembled from β-lactam/adamantane-containing guest molecule with host polymeric cyclodextrin (PCD). An advantage of this hydrogel is that because of the molecular association of polymeric cyclodextrin and adamantane, the supramolecular hydrogels self-heal without any external stimuli after the hydrogels are severed. The invention also provides methods of making the hydrogel, methods of making the synthesis intermediates, and methods of diagnosis or treatment of β-lactamase-containing bacteria.

## Claims

### Claim 1

A “host-guest” supramolecular hydrogel, comprising:
an AAm/NVP interpenetrating polymer network (IPN), with supramolecular cross-linkers assembled from
(a) β-lactam/adamantane-containing guest molecule;
(b) and host polymer.

### Claim at position 2

1-8. (canceled)

### Claim 2 (depends on 1)

The “host-guest” supramolecular hydrogel of claim 1, wherein the hydrogels exhibit or can exhibit β-lactamase-responsive degradation due to β-lactam ring hydrolysis, causing cleavage of the guest molecules in the presence of or when contacted by β-lactamase enzyme.

### Claim 3 (depends on 1)

The “host-guest” supramolecular hydrogel of claim 1, wherein the hydrogels exhibit or can exhibit β-lactamase-responsive degradation due to β-lactam ring hydrolysis, causing cleavage of the guest molecules in the presence of or when contacted by β-lactamase-producing bacteria.

### Claim 4 (depends on 1)

The “host-guest” supramolecular hydrogel of claim 1, wherein the host polymer is a poly-carboxymethyl-β-cyclodextrin (PCD).

### Claim 5

A method of fabricating a “host-guest” supramolecular hydrogel, comprising the step of combining a AAm/NVP interpenetrating polymer network with supramolecular cross-linker assembled from β-lactam/adamantane-containing guest molecules, wherein the two adamantane moieties form cross-links between the polymeric cavities.

### Claim 6

An acrylamide/N-vinylpyrrolidinone bifunctional guest molecule.

### Claim 7 (depends on 1)

The hydrogel of claim 1 for use in the diagnosis of the presence of β-lactamase-producing bacteria.

### Claim 8 (depends on 1)

The hydrogel of claim 1 for use in the treatment of a disease or condition caused by β-lactamase-producing bacteria.

### Claim 9

A β-lactamase responsive hydrogel that releases an antibiotic in the presence of a β-lactamase producing bacteria, the hydrogel comprising
a polymer crosslinked with one or more molecules comprising one or more β-lactams; and
nanoparticles comprising an antibiotic wherein the nanoparticles are encapsulated in the polymer.

### Claim 10 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel exhibits β-lactamase-responsive degradation due to a β-lactam ring hydrolysis, causing cleavage of the crosslinker when contacted by β-lactamase enzyme.

### Claim 11 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel exhibits β-lactamase-responsive degradation due to a β-lactam ring hydrolysis, causing cleavage of the crosslinker when contacted by β-lactamase-producing bacteria.

### Claim 12 (depends on 9)

The hydrogel of claim 9, wherein the polymer comprises a poly-carboxymethyl-β-cyclodextrin (PCD) or poly(ethylene glycol) derivative.

### Claim 13 (depends on 9)

The hydrogel of claim 9 for use in a diagnosis of a presence of a β-lactamase-producing bacteria.

### Claim 14 (depends on 9)

The hydrogel of claim 9 for use in a treatment of a disease or condition caused by a β-lactamase-producing bacteria.

### Claim 15 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel is suitable for an application to a wound, and wherein the hydrogel is stable after the application to the wound until the hydrogel is contacted by the β-lactamase-producing bacteria.

### Claim 16 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel is suitable for a prophylactic wound dressing or a prophylactic skin dressing, the dressing operative to release an antibiotic when the dressing is contacted by a β-lactamase-producing bacteria.

### Claim 17 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel does not cause an antibiotic resistance in one or more bacteria that are contacted by the hydrogel when the antibiotic is not released from the hydrogel or when the one or more bacteria do not comprise bacteria that are β-lactamase-producing bacteria.

### Claim 18 (depends on 9)

The hydrogel of claim 9, wherein the hydrogel will provide a complete degradation of the hydrogel when the hydrogel is incubated with a culture of a β-lactamase-producing bacteria in approximately seventy-two hours; and wherein the hydrogel will remain stable over this time of seventy-two hours when incubated with a non-β-lactamase-producing bacteria.

### Claim 19

A method of fabricating a β-lactamase responsive hydrogel that releases an antibiotic in the presence of a β-lactamase producing bacteria, the method comprising
combining a polymer, a cross-linker comprising β-lactam containing molecules, and nanoparticles comprising an antibiotic;
wherein the β-lactam containing molecules form cross-links between the host polymer thereby encapsulating the nanoparticles within crosslinked polymer.
